Business
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, United Kingdom. Only 26 abstracts were chosen for mini-oral presentation this year, marking a major milestone for HanchorBio as it delivers its firs
About this update from Cisco Systems, Inc.
[{"type":"text","content":"International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, United Kingdom. Only 26 abstracts were chosen for mini-oral presentation this year, marking a major milestone for HanchorBio as it delivers its first-ever oral presentation of clinical data at an international oncology congress, following its prior preclinical oral presentation of HCB101 at CSCO 2022.","length":726,"tagName":"p"},{"type":"image","alt":"HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025","displaySize":"","headline":null,"caption":"HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":100,"url":"https://media.zenfs.com/en/prnewswire.com/a661f862503bc7e24a3055b7c8cac802"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sYzc4lcHn9wUg30bpBDcFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a661f862503bc7e24a3055b7c8cac802","width":400,"height":100}},"href":"https://mma.prnewswire.com/media/2842512/HanchorBio_Announces_Oral_Presentation_of_HCB101_at_ESMO.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The ESMO Immuno-Oncology Congress is Europe's premier meeting dedicated exclusively to immuno-oncology science, distinct from the broader ESMO Annual Congress. While the annual ESMO meeting spans all oncology disciplines, ESMO-IO focuses on immune mechanisms, translational innovation, and next-generation therapeutic strategies across innate and adaptive immunity.","length":369,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"text","content":"Abstract ID: 242MOTitle: HCB101, a Differentiated ...